Evidence map›Paper›PMID 38518098›Full record

ArticleJournal of the National Cancer Institute2024

Racial and ethnic associations with comprehensive cancer center access and clinical trial enrollment for acute leukemia.

Andrew Hantel, Andrew M Brunner, Jesse J Plascak, Hajime Uno, Juan C Varela, Marlise R Luskin, Timothy R Rebbeck, Richard M Stone, Christopher S Lathan, Daniel J DeAngelo and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
13.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Andrew HantelDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-9612-3643
Andrew M BrunnerDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Jesse J PlascakDepartment of Internal Medicine, Division of Cancer Prevention and Control, The Ohio State University, Columbus, OH, USA.
Hajime UnoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Juan C VarelaDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Marlise R LuskinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Timothy R RebbeckDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-4799-1900
Richard M StoneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Christopher S LathanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Daniel J DeAngeloDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Gregory A AbelDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Dana-Farber Cancer Institute · USBeth Israel Deaconess Medical Center · USHarvard University · USMassachusetts General Hospital · USThe Ohio State University · US

Funding

TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI SCOTT A ARMSTRONG · 1996 to 2026
$52.5M
Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel InterventionK08CA273043 · NCI · DANA-FARBER CANCER INST · PI Andrew Hantel · 2022 to 2026
$1.2M
American Society of Clinical Oncology Career DevelopmentConquer Cancer FoundationNCI NIH HHS K08 CA273043NCI NIH HHS P01 CA066996NIH HHS K08 CA273043Rieder Family Fellowship in Acute Lymphoblastic Lymphoma
6 · The paper itself

Abstract

backgroundClinical trial participation at Comprehensive Cancer Centers (CCC) is inequitable for minoritized racial and ethnic groups with acute leukemia. CCCs care for a high proportion of adults with acute leukemia. It is unclear if participation inequities are due to CCC access, post-access enrollment, or both.

methodsWe conducted a retrospective cohort study of adults with acute leukemia (2010-2019) residing within Massachusetts, the designated catchment area of the Dana-Farber/Harvard Cancer Center (DF/HCC). Individuals were categorized as non-Hispanic Asian (NHA), Black (NHB), White (NHW), Hispanic White (HW), or Other. Decomposition analyses assessed covariate contributions to disparities in (1) access to DF/HCC care and (2) post-access enrollment.

resultsOf 3698 individuals with acute leukemia, 85.9% were NHW, 4.5% HW, 4.3% NHB, 3.7% NHA, and 1.3% Other. Access was lower for HW (age- and sex-adjusted OR = 0.64, 95% CI = 0.45 to 0.90) and reduced post-access enrollment for HW (aOR = 0.54, 95% CI =0.34 to 0.86) and NHB (aOR = 0.60, 95% CI = 0.39 to 0.92) compared to NHW. Payor and socioeconomic status (SES) accounted for 25.2% and 21.2% of the +1.1% absolute difference in HW access. Marital status and SES accounted for 8.0% and 7.0% of the -8.8% absolute disparity in HW enrollment; 76.4% of the disparity was unexplained. SES and marital status accounted for 8.2% and 7.1% of the -9.1% absolute disparity in NHB enrollment; 73.0% of the disparity was unexplained.

conclusionsA substantial proportion of racial and ethnic inequities in acute leukemia trial enrollment at CCCs are from post-access enrollment, the majority of which was not explained by sociodemographic factors.

Indexed as

Cancer Care FacilitiesClinical Trials as TopicHealth Services AccessibilityAdultAgedEthnicityFemaleHealthcare DisparitiesHumansLeukemiaLeukemia, Myeloid, AcuteMaleMassachusettsMiddle AgedRacial GroupsRetrospective Studies

Identifiers

PMID38518098
PMCPMC11223832
OpenAlexW4393066208

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.